

Referências

- 1- K RAUSE MM, MAHAN KK. **Alimentação, Nutrição e Dietoterapia** New York: Sauders Company, 1998: 72-7.
- 2- SHILS ME. **Tratado de Nutrição Moderna na Saúde e na Doença** New York: Manole, 2003: 351-67.
- 3- ZALMAN AS. Metabolism of Vitamin D. **Up to Date**; 2002, 11(3): 1-4.
- 4- HOLICK MF. Vitamin D: biosynthesis, metabolism and mode of action. In: DeGroot LJ, ED. **Endocrinology**, vol2. New York. Grune e Statton, 1989; 902-26.
- 5- EISMAN JA. 1-25-Hidroxyvitamin D3 in human cancer cells in vitamin D. In Kuman R, ed. **Vitamin D: basis and clinical aspects**. Boston: Martins Nijhoff, 1984; 365-82.
- 6- PLATZ EA, HANKINSON SE, HOLLIS BW, et al. Plasma 1,25- dihydroxy and 25-hydroxvitamin D and adenomatous polyps of the distal colorectum. **Cancer Epidemiol Biomarkers Prev** 2000; 9: 1059-65. Abstract.
- 7- MILLER GJ, STAPLETON GE, HOUMIEL KL, et al. Specific receptors for vitamin D3 in human prostatic carcinoma cells. In: **Molecular and cellular biology of prostate cancer** New York: Plenum Press; 1991: 253-9.
- 8- KONETY BR, JOHNSON CS, TRUMP DL, et al. Vitamin D in the prevention and treatment of prostrate cancer. **Semin Urol Oncol** 1999; 17: 77-84, with permission **Diabetologia** 1999;4251-4.
- 9- ZHUANG SH, BURNSTEIN KL. Antiproliferative effect of 1,25 dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin dependent kinase 2 activity and persistent G1 accumulation **Endocrinology** 1998; 139:1197-207.
- 10- HYPONEN E, LAARAE, REUNANENA, JARVELIN MR, VIRTANEN SM. Intake of vitamin d and risk of type 1 diabetes: a birth-cohort study. **Lancet** 2001; 358:1500-3.
- 11- YU WD, MCEL WAIN, MODZELEWSKI RA, et al. Enhancement of 1,25-dihydroxyvitamin D3 mediated antitumor activity with desamethasone. **J Natl Cancer Inst** 1998; 90: 134-41.
- 12- GLOTH FM, GUNBERG CM, HOLLINSOM BW. Vitamin D deficiency in housebound elderly person. **JAMA** 1995; 274: 1683-6.
- 13- THOMAS MK, LLOYD DM. Hypovitaminosis D in medical inpatients **New Engl JM** 1998; 777-83.
- 14- ZALMAN SA. Causes of vitamin D deficiency and resistance. **Up to Date**; 2002, 11(3).
- 15- R BOUILLON, WH OKAMURA, AW NORMAN. Structure-function relationships in the vitamin D endocrine system. **Endocr Rev** 1995 16: 200-257.
- 16- ALPER GURLEK, MARK R. PITTELKOW, RAJIV KUMAR Modulation of Growth Factor/Cytokine Synthesis and Signaling by 1,25-Dihydroxyvitamin D₃: Implications in Cell Growth and Differentiation **Endocr. Rev.**, 2002; 23: 763 – 786.
- 17- SCHRADER M, MULLER KM, CARLBERG C Specificity and flexibility of vitamin D signaling. Modulation of the activation of natural vitamin D response elements by thyroid hormone **J Biol Chem** 1994;269:5501–5504.
- 18- VEENSTRA TD, PITTELKOW MR, KUMAR R Regulation of cellular growth by 1,25-dihydroxyvitamin D₃-mediated growth factor expression. **News Physiol Sci** 1999;14:37–40.
- 19- BIKLE DD, PILLAI S 1993 Vitamin D, calcium, and epidermal differentiation. **Endocr Rev** 1993;14:3–19.
- 20- NAVES M,HERNANDEZ DA Effect of VDR gene polymorphisms on osteocalcin secretion in calcitriol-stimulated human osteoblasts. **Kidney Int**; 2003;85:S23-S25.
- 21- OKAMURA WH, DO S,KIM H, JEGANATHAN S Conformationally restrict mimics of Vitamin D rotamers. **Steroids** 2000; 173-179.

Revisão encomendada em 02-2004

Recebido em 05-04-2004

Revisado em 19-04-2004

Aceito em 27-04-2004